CraniUS Appoints World Leading Neurosurgeon to Join Board of Directors
Dr. Henry Brem joins CraniUS Board of Directors in further enhancing its mission to facilitate chronic and direct medicine delivery for treating brain disease.
BALTIMORE, Nov. 15, 2022 /PRNewswire/ -- CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain disease, announced today the appointment of Henry Brem, MD to its accomplished Board of Directors.
As the Harvey Cushing Professor of Neurosurgery and Neurosurgeon-in-Chief at The Johns Hopkins Hospital, Dr. Brem brings along a wealth of knowledge and unmatched experience in Neurosurgery, Neuro-oncology, and Neurotechnology development.
As per Mike Maglin, the CEO of CraniUS, "Dr. Brem is a well-respected pioneer in neurosurgery and played a key role in laying down the early foundation for CraniUS by inventing the Gliadel® wafer for direct chemotherapy placement at time of brain tumor surgery. As such, we are honored to be working together to shift the paradigm and revolutionize the way we deliver medicines to those suffering from chronic brain diseases."